N4 Pharma Management
Management criteria checks 3/4
N4 Pharma's CEO is Nigel Theobald, appointed in Jan 2014, has a tenure of 10.83 years. total yearly compensation is £82.50K, comprised of 100% salary and 0% bonuses, including company stock and options. directly owns 4.3% of the company’s shares, worth €132.72K. The average tenure of the management team and the board of directors is 5.5 years and 5.5 years respectively.
Key information
Nigel Theobald
Chief executive officer
UK£82.5k
Total compensation
| CEO salary percentage | 100.0% |
| CEO tenure | 10.8yrs |
| CEO ownership | 4.3% |
| Management average tenure | 5.5yrs |
| Board average tenure | 5.5yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -UK£1m |
| Mar 31 2024 | n/a | n/a | -UK£1m |
| Dec 31 2023 | UK£83k | UK£83k | -UK£1m |
| Sep 30 2023 | n/a | n/a | -UK£1m |
| Jun 30 2023 | n/a | n/a | -UK£925k |
| Mar 31 2023 | n/a | n/a | -UK£977k |
| Dec 31 2022 | UK£78k | UK£78k | -UK£1m |
| Sep 30 2022 | n/a | n/a | -UK£1m |
| Jun 30 2022 | n/a | n/a | -UK£1m |
| Mar 31 2022 | n/a | n/a | -UK£1m |
| Dec 31 2021 | UK£75k | UK£75k | -UK£2m |
| Sep 30 2021 | n/a | n/a | -UK£2m |
| Jun 30 2021 | n/a | n/a | -UK£2m |
| Mar 31 2021 | n/a | n/a | -UK£2m |
| Dec 31 2020 | UK£72k | UK£72k | -UK£1m |
| Sep 30 2020 | n/a | n/a | -UK£1m |
| Jun 30 2020 | n/a | n/a | -UK£863k |
| Mar 31 2020 | n/a | n/a | -UK£869k |
| Dec 31 2019 | UK£70k | UK£70k | -UK£876k |
| Sep 30 2019 | n/a | n/a | -UK£1m |
| Jun 30 2019 | n/a | n/a | -UK£1m |
| Mar 31 2019 | n/a | n/a | -UK£1m |
| Dec 31 2018 | UK£70k | UK£70k | -UK£1m |
Compensation vs Market: Nigel's total compensation ($USD107.10K) is below average for companies of similar size in the German market ($USD483.75K).
Compensation vs Earnings: Nigel's compensation has increased whilst the company is unprofitable.
CEO
Nigel Theobald (60 yo)
10.8yrs
Tenure
UK£82,500
Compensation
Mr. Nigel James Theobald has been Chief Executive Officer of N4 Pharma Plc since May 3, 2017 and serves as its Executive Director. Mr. Theobald served as the Head of Emerge Marketing Ltd., for Alltracel Ph...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | 10.8yrs | UK£82.50k | 4.3% € 132.7k | |
| Executive Director & Technical Director | 5.5yrs | UK£51.22k | no data | |
| Executive Director | 4.3yrs | UK£45.72k | 0.036% € 1.1k | |
| Head of CMC Development | 4.8yrs | no data | no data | |
| Consultant | 5.8yrs | no data | no data |
5.5yrs
Average Tenure
60yo
Average Age
Experienced Management: 0GO's management team is seasoned and experienced (5.5 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | no data | UK£82.50k | 4.3% € 132.7k | |
| Executive Director & Technical Director | 7.5yrs | UK£51.22k | no data | |
| Executive Director | no data | UK£45.72k | 0.036% € 1.1k | |
| Independent Non-Executive Director | less than a year | no data | no data | |
| Independent Non-Executive Chairman | 5.5yrs | UK£24.00k | no data |
5.5yrs
Average Tenure
60yo
Average Age
Experienced Board: 0GO's board of directors are considered experienced (5.5 years average tenure).